文章：

胃癌免疫治疗新进展

Recent advances in immune therapies for gastric cancer 

原文发布日期：2021-03-04 

英文摘要：

Gastric cancer (GC) is an aggressive malignancy that is the third leading cause of cancer mortality worldwide. Localized GC can be cured with surgery, but most patients present with more advanced non-operable disease. Until recently, treatment options for relapsed and refractory advanced GC have been limited to combination chemotherapy regimens, HER-2 directed therapy, and radiation, which lead to few durable responses. Over the past decade, there have been significant advances in our understanding of the molecular and immune pathogenesis of GC. The infectious agents Epstein-Barr virus and Helicobacter pylori perturb the gastric mucosa immune equilibrium, which creates a microenvironment that favors GC tumorigenesis and evasion of immune surveillance. Insights into immune mechanisms of GC have translated into novel therapeutics, including immune checkpoint inhibitors, which have become a treatment option for select patients with GC. Furthermore, chimeric antigen receptor T-cell therapies have emerged as a breakthrough treatment for many cancers, with recent studies showing this to be a potential therapy for GC. In this review, we summarize the current state of knowledge on immune mechanisms of GC and the status of emerging immunotherapies to treat this aggressive cancer, as well as outline current challenges and directions for future research. 

摘要翻译：

胃癌（GC）是一种侵袭性恶性肿瘤，在全球癌症相关死亡原因中位列第三。局限性胃癌可通过手术治愈，但多数患者就诊时已发展为更晚期的不宜手术疾病。直至近期，复发性和难治性晚期胃癌的治疗手段仅限于联合化疗方案、HER-2靶向治疗及放射治疗，且难以产生持久的治疗反应。过去十年中，我们对胃癌分子及免疫发病机制的认识取得了重大进展。Epstein-Barr病毒和幽门螺杆菌等感染源会破坏胃黏膜免疫平衡，形成有利于胃癌发生和免疫监视逃逸的微环境。对胃癌免疫机制的深入理解已转化为新型治疗方法，包括免疫检查点抑制剂——现已成为特定胃癌患者的治疗选择之一。此外，嵌合抗原受体T细胞疗法已成为多种癌症的突破性治疗手段，近期研究表明该疗法也可能成为胃癌的潜在治疗选择。本综述将总结当前对胃癌免疫机制的认识水平、治疗该侵袭性癌症的新兴免疫疗法进展，并概述当前面临的挑战及未来研究方向。

原文链接：

Recent advances in immune therapies for gastric cancer